NCT00315237 - Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract | Biotech Hunter

Enrollment

364

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Transitional Cell Carcinoma of the Urothelial TractBladder CancerBladder Neoplasms

Interventions

DRUG

vinflunine and best supportive care

solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration

Trial Locations (10)

Local Institution, Calgary

Local Institution, Edmonton

Local Institution, Vancouver

Local Institution, Victoria

Local Institution, Brampton

Local Institution, Hamilton

Local Institution, Kingston

Local Institution, London

Local Institution, Toronto

Local Institution, Montreal